Grünenthal uses its own and third-party cookies to improve the browsing experience, offer personalized content and improve its services. We use analytics scripts which set tracking cookie, but we will activate these services only with your consent. If you press the button “Accept”, you consent to the use of these analytics scripts.

You can withdraw your consent at any time. To do so, please modify your configurations on this website by following this link to our privacy statement with the configuration options:
Go to settings

Accept

;

Where we come from

Although firmly rooted in Germany, today we are very much a growing global business. An integrated research and development company, we have an enviable track record of bringing effective pain treatments and state-of-the-art technologies to patients. Our high level of investment in R&D is testament to our unwavering commitment to innovation.

1947 Penicillin

Grünenthal is the first company in Germany to register penicillin after World War II

1957 Thalidomide

Thalidomide is launched; it was withdrawn from market in 1961. Since its withdrawal from the market, thalidomide and its tragic consequences have been part of our history – and they always will be. We support those affected by the tragedy and work to improve their daily lives.

1977 Tramal®

Tramal® is launched; it has since become one of the most frequently prescribed central acting analgesics worldwide

2001 Transtec®

Transtec®, an analgesic for chronic pain, is launched in Europe. The innovative transdermal patch with a polymer-based matrix system allows the patient to easily and safely handle

2003 Zaldiar®

Zaldiar® the first fixed-dose analgesic containing paracetamol and a small dose of tramadol used for the treatment of acute pain is launched globally

2007 Versatis®

Versatis® is launched in the EU, a topically acting lidocaine patch used for the treatment of neuropathic pain after herpes zoster

2010 Palexia® retard

First launch of Palexia® retard in Europe: our tapentadol medication was the first innovative molecule in the centrally acting analgesic class approved in more than 25 years

2014 Arcoxia®

We begin to distribute Arcoxia® in several European countries and start to offer an innovative therapy for the treatment of pain with an inflammatory component

2017 Zomig®

We enter into an agreement with AstraZeneca for the global rights to Zomig® (Zolmitriptan), excluding Japan, a treatment used for the acute treatment of migraines and cluster headaches. This adds
another major pain indication to our portfolio

2017 Adhesys Medical

We acquire Adhesys Medical GmbH and its US-based affiliate Adhesys Medical Inc., a medical device startup company focused on the development of in-surgery adhesives, expanding our pipeline of medical devices for business with surgeons

2018 NexiumTM and VimovoTM

With the acquisition of the pain-related brands NexiumTM and VimovoTM, we conclude the biggest single investment in the history of the company. This acquisition significantly strengthens our leading position in pain management

2018 QutenzaTM

We establish our own commercial footprint in the United States by acquiring the US-rights for QutenzaTM (capsaicin) 8% patch

Thalidomide

Thalidomide will always be a significant part of our company history.
... Visit website